Report LibraryAll Reports
Datamonitor Healthcare Oncology Disease Analysis: Head and Neck Cancer
March 26, 2021
Head and neck squamous cell carcinoma (HNSCC) tumors are highly immunogenic and have elevated expression of immune checkpoint modulators. As such, there has been much interest in the development of immunotherapies to allow for targeted treatment programs.
Erbitux, once among the dominant branded systemic therapies for HNC, is being eclipsed by newer checkpoint inhibitors. Erbitux is approved for use in combination with radiation therapy to treat patients with unresectable HNSCC and both first- and second-line recurrent/metastatic HNSCC as a single agent and alongside chemotherapy.
This Datamonitor Healthcare report contains a Disease Analysis module.
|Indications Covered:||Head and Neck Cancer|